During their talk, Dr. Hamilton and Mr. Green discussed the impact of the Sovaldi launch and other upcoming blockbuster launches on how health plans monitor and plan for new launches. Dr. Hamilton anticipated a future where payers refuse guidelines from groups like AASLD. Mr. Green noted a change in the calculus for new medicines from cost:benefit or cost:efficiency ratios to a more basic question: “can we afford the out-of-pocket cost of reaping long-term benefits?” They concluded that plans will increase advance surveillance and post-launch control of medicines that threaten to increase cost of drug therapy dramatically.
October 16, 2014 — RG+A announced formal plans to release “Winning and Losing with Payers”, the study that served as the platform for the firm’s presentation it gave at the Pharma CI Conference and Exhibition, September 9, 2014 in Parsippany, NJ. The paper identified key success factors in building contracting relationships and, separately, partnerships with US insurers. Results […]